Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$557.32M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$571.13M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$548.51M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$578.40M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$538.01M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$583.31M
Return on Equity (ROE)
-11.56%
TTM Avg
-11.05%
3Y Avg
-6.83%
5Y Avg
-8.10%
Market Cap
$584.48M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$533.04M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| CorMedix Inc. (CRMD)vs › | $571.13M | 40.62% | 9.52% | -25.24% | -32.61% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | 91.17% | 180.92% | 76.31% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | N/A | 161.13% | 93.89% | 96.07% |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A | 6.49% | 6.51% | -75.00% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | -11.56% | -11.05% | -6.83% | -8.10% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | -8.42% | -4.61% | -3.17% | 11.46% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -13.64% | -19.13% | -73.22% | -63.52% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.44% | -17.98% | 71.24% | -6.51% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
